|
Post by otherottawaguy on Jan 24, 2016 9:44:53 GMT -5
Maybe we could also have a fourth person on stage as well. He would have to be dressed like a french mime (black and white with a red beret), and he would have the same setting as the others, but instead of commencing with the demonstration with the others he would go over to a sand box on stage left for some exercise filling sandbags with a silver spade and then profuse to be too tired too continue upon which he would retire to take a nap on a couch that has the mannkind logo embroider on it...
|
|
|
Post by garrett on Jan 24, 2016 9:55:17 GMT -5
Considering the conference is the last month of the 2nd quarter, my fear is they declare BK a month or 2 before that. But it's an interesting idea. Just not sure we will be able to get that far and the only thing that will give me confidence we will is back over 2.00 a share by feb or march. And why do you think they will need to file bankruptcy?
|
|
|
Post by centralcoastinvestor on Jan 24, 2016 10:11:16 GMT -5
Ripano, This is exactly what I am talking about. I am glad you remembered and posted this. Afrezza is a truly remarkable diabetes drug. I think most on this board would agree that one of the biggest problems Mannkind faces is that hardly any diabetics know about it. That needs to change and quickly. It makes me so mad that Sanofi wasted a year of oppotunities to get the word out. I just wish Mannkind could develop a roadshow that demonstrates the miracle. And get the CGM companies like Dexcom to partner with us to do it.
|
|
|
Post by kball on Jan 24, 2016 10:17:23 GMT -5
Considering the conference is the last month of the 2nd quarter, my fear is they declare BK a month or 2 before that. But it's an interesting idea. Just not sure we will be able to get that far and the only thing that will give me confidence we will is back over 2.00 a share by feb or march. And why do you think they will need to file bankruptcy? May be forced to by hardball playing Deerfield is the biggest reason
|
|
|
Post by agedhippie on Jan 24, 2016 10:26:45 GMT -5
Ripano, This is exactly what I am talking about. I am glad you remembered and posted this. Afrezza is a truly remarkable diabetes drug. I think most on this board would agree that one of the biggest problems Mannkind faces is that hardly any diabetics know about it. That needs to change and quickly. It makes me so mad that Sanofi wasted a year of oppotunities to get the word out. I just wish Mannkind could develop a roadshow that demonstrates the miracle. And get the CGM companies like Dexcom to partner with us to do it. Getting the word out is a problem. I find it hard to believe that any diabetic on social media is unaware of Afrezza between Tudiabetes, Twitter, and general chatter. How you reach everyone else, who are the vast majority, is an open question since obviously they are not on social media or they would be aware. Putting that aside for the moment that still leaves doctors unwilling to prescribe, and insurers unwilling to pay. There also seems to be this idea that CGMs are everywhere which is utterly wrong. Dexcom has between 150,000 and 100,000 users worldwide.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 24, 2016 10:28:59 GMT -5
And why do you think they will need to file bankruptcy? May be forced to by hardball playing Deerfield is the biggest reason lol Matt clarified that only 5mil payment is due to Deerfield this year.. Where did u get this?
|
|
|
Post by centralcoastinvestor on Jan 24, 2016 10:40:05 GMT -5
Ripano, This is exactly what I am talking about. I am glad you remembered and posted this. Afrezza is a truly remarkable diabetes drug. I think most on this board would agree that one of the biggest problems Mannkind faces is that hardly any diabetics know about it. That needs to change and quickly. It makes me so mad that Sanofi wasted a year of oppotunities to get the word out. I just wish Mannkind could develop a roadshow that demonstrates the miracle. And get the CGM companies like Dexcom to partner with us to do it. Getting the word out is a problem. I find it hard to believe that any diabetic on social media is unaware of Afrezza between Tudiabetes, Twitter, and general chatter. How you reach everyone else, who are the vast majority, is an open question since obviously they are not on social media or they would be aware. Putting that aside for the moment that still leaves doctors unwilling to prescribe, and insurers unwilling to pay. There also seems to be this idea that CGMs are everywhere which is utterly wrong. Dexcom has between 150,000 and 100,000 users worldwide. Which is why partnering with CGM companies on advertising makes a lot of sense. It's a win win.
|
|
|
Post by suebeeee1 on Jan 24, 2016 11:55:56 GMT -5
Insurance companies rarely cover the cost for CGMs. When you are diagnosed as a diabetic, often doctors hand you a free glucose meter. The companies that make them provide them to the doctors for free. The cost of testing strips will pay off the meter many many times over. This is the reason sales of CGMs are so free or cheap. In reality, most diabetics don't need a CGM. It's a nice device to have and it makes taking care of the disease a bit easier, maybe. Most diabetics do not stick themselves enough to financially or operationally make these things an important part of their treatment protocol. Who wants to be continually attached to an external machine? After Google makes contact lenses that transmit bg levels to your phone, it may be a bit more convenient. But necessary or even desirable? Probably not.
CGM companies trying to make sales outside of insurance companies may find it useful to advertise with Afrezza, which would help make the transition from an injectable to an oral med more convenient and alleviate fears that Afrezza isn't working. It would help fine tune dosages and timing... For the two weeks it takes to transition successfully. Insurance companies still aren't going to pay the exorbitant CGM cost for two weeks of need.
|
|
|
Post by kball on Jan 24, 2016 12:16:48 GMT -5
May be forced to by hardball playing Deerfield is the biggest reason lol Matt clarified that only 5mil payment is due to Deerfield this year.. Where did u get this?How about by paying attention to everything thats happened in the last 5 months. And i said they MAY be forced to. Not will. (Though i honestly think they will declare by end of june if not earlier)
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 24, 2016 12:24:51 GMT -5
lol Matt clarified that only 5mil payment is due to Deerfield this year.. Where did u get this?How about by paying attention to everything thats happened in the last 5 months. And i said they MAY be forced to. Not will. (Though i honestly think they will declare by end of june if not earlier) No one can force into BK as long s they satisfy creditors original terms so please stop posting your dooms day scenario with out posting the due dollar amounts and how Mannkind wouldn't be able to pay them
|
|
|
Post by mnkdorbust on Jan 24, 2016 13:02:11 GMT -5
I heard Matt say roughly 5mil due this year as well. I though he also said roughly the same the following year. (i'm not positive on the next year amount).
|
|
|
Post by edvarney on Jan 24, 2016 13:20:04 GMT -5
I have been following the proboards since FDA approval of Afrezza.. I like to do my own DD and just listen to others ideas on this whole evolution of Mannkind. Since I am just an older citizen who retired from Marketing and Sales with a National Corp; I cant help but make a mention here on this latest post about a small group all eating before a larger setting of an audience observing live results of Afrezza in action! on a large screen showing CGM graph movement of BG.
If I had been involved in this early marketing endeavor of Afrezza; after learning and collecting the data from Sam Finta's early adopters group, there is little doubt in my mind that this "show and tell" approach across the country with smaller setting of 20-30 involved medical/diabetic field pros. in attendance would be wildly successful for the marketing endeavor. in fact, the TCOYD (take control of your Diabetes) platform is a perfect example of what could all ready have been accomplished!!! They even had the dinners our lunches set up for all attendees at those meeting just to get people through the door.!!
I still believe in the old fashion way of getting through to the end user and you really do have to use show and tell with many products yet today...Its not to late for Afrezza! but, lets get some folks in marketing that really care about the success of Afrezza, ( namely, users!) who have the raw experience and can speak from the heart and show live results now with new technology in hand.
This task is really not that difficult to do on a large scale across America! and certainly not expensive to achieve what is needed, BELIEVERS,will become users.
Thank You,
|
|
|
Post by agedhippie on Jan 24, 2016 13:28:58 GMT -5
Insurance companies rarely cover the cost for CGMs. When you are diagnosed as a diabetic, often doctors hand you a free glucose meter. The companies that make them provide them to the doctors for free. The cost of testing strips will pay off the meter many many times over. This is the reason sales of CGMs are so free or cheap. In reality, most diabetics don't need a CGM. It's a nice device to have and it makes taking care of the disease a bit easier, maybe. Most diabetics do not stick themselves enough to financially or operationally make these things an important part of their treatment protocol. Who wants to be continually attached to an external machine? After Google makes contact lenses that transmit bg levels to your phone, it may be a bit more convenient. But necessary or even desirable? Probably not. I think you may be confusing blood glucose meters with CGMs because CGMs definitely are not free! Typically a Dexcom is around $650 for the receiver which is the bit you keep. The consumables for a CGM are the transmitter (a couple a year) and about 50 sensors a year. The attraction of a CGM is that you can tell if you are rising or dropping and how fast. This is a big deal because if I test at 140 before a meal I will take extra insulin to bring that down. With a CGM for example I could see that I am dropping quickly and rather than taking extra insulin I should to take much less or I will go low in a while. You can do without it, and I mostly do because of the cost, but it reduces my A1c by about 0.4 (6.6 to 6.2 last time) when I use it. I agree that if you are not on insulin, and the large majority of diabetics are not, it is of limited use.
|
|
|
Post by kc on Jan 24, 2016 13:52:43 GMT -5
I would hope and plan that Mannkind will have a very good presence at the show perhaps with a a new partner or owner. Being an annual show they want to get the biggest bang for their investment dollar. They can't afford the floor space commitment that Sanofi had. So they will have to have a nice but modest booth. The key is visibility and acessability.
|
|
|
Post by suebeeee1 on Jan 24, 2016 15:14:43 GMT -5
Insurance companies rarely cover the cost for CGMs. When you are diagnosed as a diabetic, often doctors hand you a free glucose meter. The companies that make them provide them to the doctors for free. The cost of testing strips will pay off the meter many many times over. This is the reason sales of CGMs are so free or cheap. In reality, most diabetics don't need a CGM. It's a nice device to have and it makes taking care of the disease a bit easier, maybe. Most diabetics do not stick themselves enough to financially or operationally make these things an important part of their treatment protocol. Who wants to be continually attached to an external machine? After Google makes contact lenses that transmit bg levels to your phone, it may be a bit more convenient. But necessary or even desirable? Probably not. I think you may be confusing blood glucose meters with CGMs because CGMs definitely are not free! Typically a Dexcom is around $650 for the receiver which is the bit you keep. The consumables for a CGM are the transmitter (a couple a year) and about 50 sensors a year. The attraction of a CGM is that you can tell if you are rising or dropping and how fast. This is a big deal because if I test at 140 before a meal I will take extra insulin to bring that down. With a CGM for example I could see that I am dropping quickly and rather than taking extra insulin I should to take much less or I will go low in a while. You can do without it, and I mostly do because of the cost, but it reduces my A1c by about 0.4 (6.6 to 6.2 last time) when I use it. I agree that if you are not on insulin, and the large majority of diabetics are not, it is of limited use. My point was, and maybe I wasn't clear enough, that blood glucose meters are free because the companies make lots of money selling strips. Whereas the insurance companies will never pay for cgms because of that reality. Many type 2s on insulin do not test nearly as often as type 1s and don't like to be hooked up constantly to a meter. While we all understand that the risk of hypis are as great for anyone on insulin, the reality is that they simply don't test as often. After the two weeks that it takes to adjust the Afrezza dose and become confident that there will be no hypoglycemia, the cgm becomes useless. Why would insurance companies pay for something that is only really needed for two weeks?
|
|